These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24139347)

  • 1. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
    Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A
    Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone supplementation does not worsen lower urinary tract symptoms.
    Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
    J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
    Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
    Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms.
    Saad F; Doros G; Haider KS; Haider A
    Investig Clin Urol; 2018 Nov; 59(6):399-409. PubMed ID: 30402573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men.
    Haider A; Gooren LJ; Padungtod P; Saad F
    Andrologia; 2009 Feb; 41(1):7-13. PubMed ID: 19143723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size.
    Yassin A; Alwani M; Al-Zoubi RM; Aboumarzouk OM; Talib R; Nettleship J; Kelly D; Albaba B
    Int Urol Nephrol; 2023 Jul; 55(7):1649-1658. PubMed ID: 37148486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
    Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
    J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years.
    Wang CC; Chancellor MB; Lin JM; Hsieh JH; Yu HJ
    BJU Int; 2010 Apr; 105(8):1136-40. PubMed ID: 19804425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
    Yassin DJ; Doros G; Hammerer PG; Yassin AA
    J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
    Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
    Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
    Park YW; Kim SB; Kwon H; Kang HC; Cho K; Lee KI; Kim YJ; Lee JH
    Urology; 2013 Sep; 82(3):674-9. PubMed ID: 23850334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone treatment and change of categories of the International prostate symptom score (IPSS) in hypogonadal patients: 12 years prospective controlled registry study.
    Yassin A; Kelly D; Nettleship J; Talib R; Al-Zoubi RM; Aboumarzouk OM; Albaba B
    Aging Male; 2023 Dec; 26(1):2220567. PubMed ID: 37287273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
    Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
    Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome.
    Giltay EJ; Tishova YA; Mskhalaya GJ; Gooren LJ; Saad F; Kalinchenko SY
    J Sex Med; 2010 Jul; 7(7):2572-82. PubMed ID: 20524974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study.
    Kalinchenko S; Vishnevskiy EL; Koval AN; Mskhalaya GJ; Saad F
    Aging Male; 2008 Jun; 11(2):57-61. PubMed ID: 18570056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
    J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.